Cargando…
Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study
Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jia...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561391/ https://www.ncbi.nlm.nih.gov/pubmed/37818186 http://dx.doi.org/10.3389/fphar.2023.1212116 |
_version_ | 1785117911866671104 |
---|---|
author | Luo, Rui Fang, Chongkai Chen, Chuyao Zhang, Ying Yao, Ruiwei Wang, Jinan Shi, Hanqian Feng, Kunliang Hu, Mingli Zhong, Chong |
author_facet | Luo, Rui Fang, Chongkai Chen, Chuyao Zhang, Ying Yao, Ruiwei Wang, Jinan Shi, Hanqian Feng, Kunliang Hu, Mingli Zhong, Chong |
author_sort | Luo, Rui |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC. |
format | Online Article Text |
id | pubmed-10561391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105613912023-10-10 Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study Luo, Rui Fang, Chongkai Chen, Chuyao Zhang, Ying Yao, Ruiwei Wang, Jinan Shi, Hanqian Feng, Kunliang Hu, Mingli Zhong, Chong Front Pharmacol Pharmacology Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC. Frontiers Media S.A. 2023-09-25 /pmc/articles/PMC10561391/ /pubmed/37818186 http://dx.doi.org/10.3389/fphar.2023.1212116 Text en Copyright © 2023 Luo, Fang, Chen, Zhang, Yao, Wang, Shi, Feng, Hu and Zhong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Luo, Rui Fang, Chongkai Chen, Chuyao Zhang, Ying Yao, Ruiwei Wang, Jinan Shi, Hanqian Feng, Kunliang Hu, Mingli Zhong, Chong Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
title | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
title_full | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
title_fullStr | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
title_full_unstemmed | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
title_short | Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
title_sort | adjuvant therapy with jianpi huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561391/ https://www.ncbi.nlm.nih.gov/pubmed/37818186 http://dx.doi.org/10.3389/fphar.2023.1212116 |
work_keys_str_mv | AT luorui adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT fangchongkai adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT chenchuyao adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT zhangying adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT yaoruiwei adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT wangjinan adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT shihanqian adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT fengkunliang adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT humingli adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy AT zhongchong adjuvanttherapywithjianpihuayudecoctionimprovesoverallandrecurrencefreesurvivalafterhepatectomyforhepatocellularcarcinomaaretrospectivepropensityscorematchingstudy |